Voucher Scheme
Phenomics Australia offers a voucher scheme to facilitate and encourage access to one or more Phenomics Australia facilities. This scheme is intended to further reduce the cost of access to a specific capability.
Pipeline Accelerator - Voucher Scheme
Access the Pipeline
Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, Phenomics Australia, Therapeutic Innovation Australia (TIA), ANSTO, Bioplatforms Australia and Microscopy Australia seamlessly support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.
To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a voucher-style scheme that supports the cost of access to a broad range of advanced capabilities. In this Pipeline Accelerator round, Phenomics Australia is partnering with Therapeutic Innovation Australia (TIA), ANSTO’s National Deuteration Facility (NDF), Bioplatforms Australia (BPA) and Microscopy Australia to expand the list of translation expertise necessary for the discovery and translation of medical research.
This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching funding (co-investment) to be provided by the applicant.
Refer to the guidelines for information on eligibility, funding levels, co-investment expectations, as well as the application and funding process. All applicants are required to complete and submit the applications online. The link to the application form can be found in the guideline document. We strongly advise you to develop your application on the provided template as the online form cannot be saved and retrieved at a later date.
Applications closed on Friday 30th of October 2026, 5pm (AEST).
Voucher scheme documents
Please click on buttons below to download the appropriate documents for the current round.
Pipeline Accelerator Acknowledgments
When one Phenomics Australia facility is used:
‘The project was supported by the Phenomics Australia’s Pipeline Accelerator voucher scheme («DOI»)’. Followed by ‘The author/s acknowledge the facilities, and the scientific and technical assistance of [insert name of node] (node ROR), [insert name of university/institute]. [Insert name of node] is supported by Phenomics Australia (https://ror.org/0201hm243). Phenomics Australia is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.’
When two Phenomics Australia facilities are used:
‘The project was supported by the Phenomics Australia’s Pipeline Accelerator voucher scheme («DOI»)’. Followed by ‘The author/s acknowledge the facilities, and the scientific and technical assistance of [insert name of nodes] (node RORs), [insert name of university/institute]. [Insert name of nodes] are supported by Phenomics Australia (https://ror.org/0201hm243). Phenomics Australia is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.’
When it’s a joint NCRIS project:
‘The project was supported by the Pipeline Accelerator voucher scheme («DOI» and TIA’s DOI if relevant)’. Followed by ‘The author/s acknowledge the facilities, and the scientific and technical assistance of [insert name of nodes] (node RORs), [insert name of university/institute]. [Insert name of node] is supported by Phenomics Australia (https://ror.org/0201hm243). [Insert name of node] is supported by Therapeutic Innovation Australia (https://ror.org/01rde0531)/ Bioplatforms Australia (https://ror.org/042gz1a70). Phenomics Australia and Therapeutic Innovation Australia/ Bioplatforms Australia are supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.’
Pipeline Accelerator Outcomes
All awarded Pipeline Accelerator projects will be listed here.
Project Metadata
| Round | Lead applicant | Affiliation | Project title | Phenomics Australia node ( Capability provider) | DOI |
|---|---|---|---|---|---|
| 2025-26 Round 2 | Miss Ava Owen | Murdoch Children's Research Institute | Generating a model of variations in female reproductive tract development using a new stem cell reporter line | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/p4dg-6s42 |
| 2025-26 Round 2 | Dr Declan Turner | Murdoch Children’s Research Institute | Developing a human iPSC-derived alveolar coculture platform to model respiratory infection and regeneration | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/tpwr-xd91 |
| 2025-26 Round 2 | Prof Gemma Kelly | Walter and Eliza Hall Institute of Medical Research | Identifying which processes activated by p53 are critical to prevent tumour development to supportthe design of novel cancer therapies | Melbourne Advanced Gene Editing Centre (ONJCRI) | https://doi.org/10.82509/t5na-pp22 |
| 2025-26 Round 2 | Dr James McKenna | Algorae Sciences | Validating the generalizability of artificial intelligence for in silico drug combination prediction | Victorian Centre for Functional Genomics (Peter Mac) | https://doi.org/10.82509/zb4b-z588 |
| 2025-26 Round 2 | Dr Jenny Fung | University of Queensland | CRISPR-Engineered Motor Neuron Disease Cell Models to Enable Target Validation and Accelerate Therapeutic Translation | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/j230-aq79 |
| 2025-26 Round 2 | Dr Kayla Wilson | University of Melbourne | Targeting Cholesin to Control Viral Immunity | Melbourne Advanced Gene Editing Centre (ONJCRI) | https://doi.org/10.82509/k9b3-5d27 |
| 2025-26 Round 2 | Dr Lara Graves | Sydney Children’s Hospitals Network | Generation of Humanised CYP21A2 Mouse Models to Enable Translational Genome Editing Therapies for Congenital Adrenal Hyperplasia | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/wq77-9y82 |
| 2025-26 Round 2 | Dr Laura Croft | Queensland University of Technology | Patient-Derived Cortical Organoids to Decipher Disease Mechanisms and Therapeutic Response in SLC6A1-Related NDD | Australian Organoid Facility (UQ),StemCore | https://doi.org/10.82509/gwzw-ct60 |
| 2025-26 Round 2 | Dr Madeleine Hardy | Australian National University | Understanding the genetic basis of Syntelencephaly | Genome Targeting Facility (ANU) | https://doi.org/10.82509/g39d-8w93 |
| 2025-26 Round 2 | Dr Nathalie Saurat | Monash University | Transcriptomic and phenotypic screening of aged human microtissues to advance Alzheimer's disease therapeutics | Victorian Centre for Functional Genomics (Peter Mac),Monash Proteomics & Metabolomics Platform | https://doi.org/10.82509/9pwg-6v56 |
| 2025-26 Round 2 | Dr Peter Johnson | Australian National University | Developing a Scalable Hydrogel Discovery Platform for 3D Cancer Modelling | ANU Centre for Therapeutic Discovery (ANU) | https://doi.org/10.82509/5dkz-5d35 |
| 2025-26 Round 2 | Dr Richard Burke | Monash University | In vivo functional characterisation of candidate pathogenic variants in ubiquitin proteasome components | Australian Transgenic Drosophila Facility (Peter Mac) | https://doi.org/10.82509/v601-kj52 |
| 2025-26 Round 2 | Dr Yi Tian Ting | Monash University | Scalable Allogeneic Tregs Platform for autoimmune diseases | Stem Cell Production Facility (VCCRI) | https://doi.org/10.82509/hcb0-6002 |
| 25_26_Round 1 | Dr Géza Berecki | Florey Institute of Neuroscience and Mental Health | Developing an inducible mouse model of neonatal encephalopathy for preclinical evaluation of sodium channel modulators | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/0xjh-9034 |
| 25_26_Round 1 | Dr Jessica Neil | University of Melbourne | Development of a high-throughput lung epithelial cell screening platform for discovery of broadly-acting antivirals against coronaviruses | Victorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/bd3x-ap91 |
| 25_26_Round 1 | Dr Kevin Watt | Murdoch Children’s Research Institute | Generation of a human stem cell model to screen for efficacy and potency of novel regenerative small molecules | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/wrk9-xb77 |
| 25_26_Round 1 | Dr Laura Ellett | The Florey Institute of Neuroscience and Mental Health | Generating a murine model of genetic prion disease relevant to Australian mutation carriers | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/amdr-k705 |
| 25_26_Round 1 | Prof. Oliver Rackham | The Kids Research Institute Australia | New preclinical models of mitochondrial disease | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/gjzk-wk86 |
| 25_26_Round 1 | Dr Ryan Leung | Murdoch Children's Research Institute | Investigating the potential of differentiation therapy for paediatric diffuse hemispheric glioma | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)andVictorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/z11c-d329 |
| 25_26_Round 1 | Dr Thanh Nha Uyen Le | Hudson Institute of Medical Research | A multi-omics strategy to reveal hidden genetic drivers in undiagnosed gonadal dysgenesis | Phenomics Australia node: Monash Genome Modification PlatformBioplatforms Australia nodes: Australian Genome Research Facility andMonash Proteomics & Metabolomics Platform | https://doi.org/10.82509/pymc-dr28 |
| 25_26_Round 1 | Dr William Roman | Monash University | Genome-Scale Functional Screen to Discover Therapeutic Targets for Muscle Atrophy and Regeneration | Victorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/vtza-hb24 |
| 24_25_Round 2 | A/Prof. Amee George | The Australian National University | Developing humanised models of Diamond Blackfan Anaemia Syndrome | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/n2kg-df45 |
| 24_25_Round 2 | Dr Ao Wen Zhuang | The University of Melbourne | Patient-derived iPSC airway epithelial assay systems to develop Jagged-1 inhibitors targeting the root cause of muco-obstructive lung diseases | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/y9ct-nr90 |
| 24_25_Round 2 | Dr Christian Makhoul | The University of Melbourne | CRISPR phenotype screen and machine learning to understand Motor Neurone Disease pathogenesis | Victorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/ntnh-1950 |
| 24_25_Round 2 | Prof. Claudia Nold | Hudson Institute of Medical Research | Novel Immunologic Intervention for Interferon Driven Autoimmune Diseases | Phenomics Australia node: Monash Organoid Program (Monash Uni)Bioplatforms Australia node: Monash Proteomics and Metabolomics Platform (Monash Uni) | https://doi.org/10.82509/kjjz-9s40 |
| 24_25_Round 2 | Dr Harriet Fitzgerald | Hudson Institute of Medical Research | Determining the role of endometrial dysfunction in endometriosis | Monash Organoid Program (Monash Uni) | https://doi.org/10.82509/bcm4-m109 |
| 24_25_Round 2 | Prof. Leanne Dibbens | University of South Australia | Identifying re-purposed drugs for KCNT1 epilepsy using cell and animal models | Australian Transgenic Drosophila Facility (PeterMac) | https://doi.org/10.82509/crw5-pw87 |
| 24_25_Round 2 | Ms Lucy Bradbury | University of Queensland | Development of a Primary CNS Lymphoma (PCNSL)-Brain Organoid co-culture model | Australian Organoid Facility (UQ) | https://doi.org/10.82509/75em-kn44 |
| 24_25_Round 2 | Dr Travis Ruan | Garvan Institute of Medical Research | Reprogramming the Breast Cancer Microenvironment to Improve Anti-Tumour Immunity | Victorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/35cy-r397 |
| 24_25_Round 2 | Dr Tan Nguyen | Walter and Eliza Hall Institute/exteRNA | Target identification of novel anti-cancer therapeutic | Phenomics Australia node: Monash Functional Genomics Platform (Monash)Bioplatforms Australia node: Drug Target Idenfitication Platform (Monash) | https://doi.org/10.82509/gsmz-x293 |
| 24_25_Round 1 | Dr Aakanksha Dixit | The University of Queensland | Developing a humanized mouse model for Multiple Sclerosis | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/g06z-nz80 |
| 24_25_Round 1 | Dr Alexander Maytum | Murdoch Children’s Research Institute | Studying enhancer function and the genetics of blood cell development from human induced pluripotent stem cells | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/xr1v-n973 |
| 24_25_Round 1 | Dr Aude Dorison | Murdoch Children’s Research Institute | Screening for new treatments for glomerular disease with a new stem cell reporter line | Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)Therapeutic Innovation Australia node: Drug Discovery Facility | https://doi.org/10.82509/5952-mk69 |
| 24_25_Round 1 | Dr Caitlin Finney | Westmead Institute for Medical Research | Testing precision medicines for Alzheimer's disease using advanced 3D human brain models | Victor Chang Stem Cell Production Facility (VCCRI) | https://doi.org/10.82509/y2gj-7v56 |
| 24_25_Round 1 | Dr Charlene M Magtoto | Walter and Eliza Hall Institute of Medical Research | Creating an immunocompetent preclinical prostate cancer model to investigate targeting a tumour-driving transcription factor to stop disease | Melbourne Advanced Genome Editing Centre (ONJCRI/WEHI) | https://doi.org/10.82509/ev4r-k893 |
| 24_25_Round 1 | Dr Denny Cottle | Monash Biomedicine Discovery Institute | Developing rapid Pharmacodynamic AURKA Targeted Protein Degrader screening mice | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/zvft-xp45 |
| 24_25_Round 1 | Dr James McNamara | Murdoch Children's Research Institute | Developing novel models of cardiomyopathy for therapeutic testing | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) and Melbourne Advanced Genome Editing Centre (ONJCRI/WEHI) | https://doi.org/10.82509/mfzq-y642 |
| 24_25_Round 1 | Dr Katharine Goodall | Murdoch Children's Research Institute | Gene therapy to cure primary immunodeficiencies | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/atd5-kg38 |
| 24_25_Round 1 | Dr Lachlan Jolly | The University of Adelaide | Overcoming Silence in Neurodevelopmental Disorder Gene Diagnosis | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) | https://doi.org/10.82509/s8dk-a066 |
| 24_25_Round 1 | Dr Lauren Elizabeth Bleakley | Florey Institute of Neuroscience and Mental Health | Engineering genetic mouse models of severe childhood epilepsy to test the efficacy of venom peptides as a therapeutic strategy | Monash Genome Modification Platform (Monash) | https://doi.org/10.82509/jx68-k477 |
| 24_25_Round 1 | Dr Sara Hlavca | Monash University | Identifying patient-specific treatments that target plasticity in colorectal cancer via high throughput screening | Victorian Centre for Functional Genomics (PeterMac) | https://doi.org/10.82509/840j-5j19 |
| 23_24_Round 2 | Dr Allara Zyberberg | Murdoch Children’s Research Institute | Developing reporter lines to enhance human kidney micro-organoids | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility | https://doi.org/10.82509/5j50-5273 |
| 23_24_Round 2 | Dr Andrew Bejoy Das | Murdoch Children’s Research Institute | High-throughput identification of targets that improve kidney organoid generation protocols | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Victorian Centre for Functional Genomics | https://doi.org/10.82509/6xez-kr46 |
| 23_24_Round 2 | Dr Chun Yuen Chow | The University of Queensland | A novel therapeutic intervention for genetic epilepsies using spider-venom peptides | Genome Engineering and Disease Modelling Service (UQ - AIBN). | https://doi.org/10.82509/tn8t-3173 |
| 23_24_Round 2 | Dr Chengxue Qin | Monash University | Development of Humanised Mice to Improve the Translatability for Cardiopulmonary Disease | Monash Genome Modification Platform | https://doi.org/10.82509/5br4-d494 |
| 23_24_Round 2 | Prof. Deborah Marsh | University of Technology Sydney | FDA-approved therapeutic compound library screen to discover new drugs to treat ARID1A mutant ovarian cancer | ANU Centre for Therapeutic Discovery | https://doi.org/10.82509/9k1d-b776 |
| 23_24_Round 2 | Dr Dilys Leung | Monash University | Identification of personalised treatment strategies for breast cancer through high-throughput screening | Victorian Centre for Functional Genomics and Monash Organoid Program | https://doi.org/10.82509/ww7y-kv68 |
| 23_24_Round 2 | Dr Laura Cook | University of Melbourne | A high throughput human organoid model to measure effects of co-cultured immune cells | Victorian Centre for Functional Genomics | https://doi.org/10.82509/8exm-f854 |
| 23_24_Round 2 | Dr Louise Robertson | The University of Adelaide | Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa | Phenomics Australia node:Â South Australia Genome Editing FacilityTherapeutic Innovation Australia node: Vector and Genome Engineering Facility | https://doi.org/10.82509/hz3j-jw23 |
| 23_24_Round 2 | Dr Natasha Kelly Tuano | Murdoch Children’s Research Institute | Deciphering the role of the kinome in skeletal muscle and their potential use as a therapeutic target in disease | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Monash Functional Genomics Platform | https://doi.org/10.82509/xsr0-z276 |
| 23_24_Round 2 | Dr Trent Woodruff | The University of Queensland | Developing new tools to enable the translation of complement therapeutics for human disease | Monash Genome Modification Platform | https://doi.org/10.82509/3205-bb24 |
| 23_24_Round 2 | Dr Yuanzhao Cao | The University of Queensland | A chloride ion channel as a novel therapeutic target for ischaemic heart disease | Monash Genome Modification Platform | https://doi.org/10.82509/rf2y-md51 |
| 23_24_Round 1 | Dr Suad Mohamed Abdirahman | Peter MacCallum Cancer Centre | High throughput screening to identify new therapeutic strategies for mucinous ovarian cancer patients | Victorian Centre for Functional Genomics | https://doi.org/10.82509/0rjn-2b18 |
| 23_24_Round 1 | Dr Nicole J. Van Bergen | Murdoch Children's Research Institute | Development of iPSC models for ASO screening for TRAPPC4 neurodevelopmental disorder | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility | https://doi.org/10.82509/52qh-h634 |
| 23_24_Round 1 | Ms Rikki Brown | Harry Perkins Institute | Generation of Oral Carcinoma Patient-Derived Organoids for Personalised Cancer Research | Perkins Cancer Biobank | https://doi.org/10.82509/megh-9025 |
| 23_24_Round 1 | Prof Helen Abud | Monash University and Cabrini Health | Personalised treatment strategies for patients with early-onset metastatic colorectal cancer | Victorian Centre for Functional Genomics and Monash Functional Genomics Platform | https://doi.org/10.82509/2b6r-gx60 |
| 23_24_Round 1 | Dr Iva Nikolic | oNKo-Innate Pty Ltd | Methodology development for high-throughput compound screening of primary human immune cell cytotoxicity in 3D | Victorian Centre for Functional Genomics | https://doi.org/10.82509/n1xy-vk83 |
| 23_24_Round 1 | Dr Remy Robert | Monash University | Development of human GPCR knock-in mice for assessment of therapeutic antibodies | Melbourne Advanced Genome Editing Centre | https://doi.org/10.82509/sfzj-8a72 |
| 23_24_Round 1 | Dr Naisana Seyedasli | University of Sydney & Centre for Cancer Research | Establishing a targeted treatment strategy using epigenetic reprogramming against adverse EMT-induced tumour plasticity in head and neck (oral) squamous cell carcinoma | Monash Genome Modification Platform | https://doi.org/10.82509/9603-1820 |
| 23_24_Round 1 | Dr Holly Voges | Murdoch Children's Research Institute | Developing a human induced pluripotent stem cell reporter line for heart valve disease modelling | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility | https://doi.org/10.82509/wbza-7b96 |
| 23_24_Round 1 | Dr Kevin Watt | Murdoch Children's Research Institute | Generation of mouse models of inherited heart failure to test the efficacy of novel stem cell based therapies | Melbourne Advanced Genome Editing Centre | https://doi.org/10.82509/tbn7-6d23 |
| 22_23_Round 2 | Prof James Hudson | QIMR Berghofer | Development of an epicardial lineage tracing human pluripotent stem cell line to identify new cardiac therapeutics | Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility | https://doi.org/10.82509/rdmn-w236 |
| 22_23_Round 2 | Dr Graham A. Mackay | The University of Melbourne | MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation | Victorian Centre for Functional Genomics | https://doi.org/10.82509/7ffy-5a63 |
| 22_23_Round 2 | Dr Brett McKinnon | The University of Queensland | High throughput screening of micro-organoids for assessing heterogeneity and precision medicine potential in endometriosis | Victorian Centre for Functional Genomics | https://doi.org/10.82509/qdke-nc06 |
| 22_23_Round 2 | Dr Svenja Pachernegg | Murdoch Children's Research Institute | Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal | Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility | https://doi.org/10.82509/wa1k-4q04 |
| 22_23_Round 2 | Dr Ada Koo | The University of Melbourne | Developing transcriptomic and morphological profiling of macrophages to mine the microbiome | Victorian Centre for Functional Genomics | https://doi.org/10.82509/xmcn-vy05 |
| 22_23_Round 2 | Dr Alexander Nicholas Combes | Monash University | New therapeutic strategies and targets to suppress acute kidney injury | Victorian Centre for Functional Genomics and Monash Functional Genomics Platform | https://doi.org/10.82509/p6pk-6q12 |
| 22_23_Round 2 | Dr Simon Preston | Anaxis Pharma Pty Ltd | Evaluating human organoids as model systems in drug development | Monash Organoid Program | https://doi.org/10.82509/5vp9-4a25 |
| 22_23_Round 2 | A/Prof Edwina McGlinn | Monash University | Tick tock, tick tock… Mechanisms pacing the Hox clock | Monash Functional Genomics Platform | https://doi.org/10.82509/h217-k558 |
| 22_23_Round 2 | Dr Zhian Chen | The University of Queensland | The role of ferroptosis and oxidative stress in regulating immunity | Monash Functional Genomics Platform | https://doi.org/10.82509/v309-sa04 |
| Round | Lead applicant | Affiliation | Project title | Phenomics Australia node ( Capability provider) | DOI |
Voucher Scheme Webinars
If you have any questions regarding Pipeline Accelerator, refer to our FAQs or check our latest info session here.
Alternatively, contact us at contact@australianphenomics.org.au
More information
For further information about the voucher scheme, please contact:
Pipeline Accelerator FAQs
Search for an answer here
Therapeutic Innovation Australia (TIA) is a national consortium of translational research infrastructure with a focus on the development of new therapeutic products such as biologics and vaccines, cell and gene therapies as well as small molecule pharmaceuticals. More information here.